Replies to post #783 on SCYNEXIS (SCYX)

[HDOGTX]

$SCYX SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) GlobeNewswire "Press Releases"
Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints
Ibrexafungerp was generally safe and well-tolerated
Positive results consistent with previously reported VANISH-303 study support anticipated NDA submission for the treatment of vulvovaginal candidiasis (VVC) in the second half of 2020
Enrollment is ongoing in the CANDLE Phase 3 study of oral ibrexafungerp for the prevention of recurrent VVC, with supplemental NDA submission planned for the second half of 2021
Conference call to be held April 21 st, 2020 at 8:30 a.m. E